Myeloma bone disease and treatment options

European Journal of Cancer

Volumn 42, Issue 11, 2006, Pages 1554-1563

  Yeh, Howard S ^a   Berenson, James R ^a  

^a INSTITUTE FOR MYELOMA AND BONE CANCER RESEARCH   (United States)

Author keywords

Bisphosphonates; Myeloma bone disease

Indexed keywords

ANALGESIC AGENT; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; CREATININE; ETIDRONIC ACID; FC RECEPTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBANDRONIC ACID; INCADRONIC ACID; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MELPHALAN; MINODRONIC ACID; NEUTRALIZING ANTIBODY; NITROGEN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PAMIDRONIC ACID; PREDNISONE; STEROID RECEPTOR COACTIVATOR 1; WNT PROTEIN; ZOLEDRONIC ACID;

ABDOMINAL PAIN; ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APPETITE DISORDER; ARTHRALGIA; ARTICLE; B CELL LYMPHOMA; BACKACHE; BIOLOGY; BONE DESTRUCTION; BONE DISEASE; BONE METASTASIS; BONE NECROSIS; BONE PAIN; BONE TURNOVER; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; CELL FUNCTION; CLINICAL FEATURE; CLINICAL TRIAL; COMPRESSION FRACTURE; CONSTIPATION; CREATININE BLOOD LEVEL; DIARRHEA; DIET THERAPY; DIZZINESS; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG INFUSION; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DYSPEPSIA; HOSPITALIZATION; HUMAN; HYPERCALCEMIA; HYPERKALEMIA; HYPERPARATHYROIDISM; HYPOCALCEMIA; HYPOMAGNESEMIA; HYPOPHOSPHATEMIA; INHIBITION KINETICS; JAW; KIDNEY FAILURE; KINESIOTHERAPY; KYPHOPLASTY; LENGTH OF STAY; LIFESTYLE; LONG TERM CARE; LOW DRUG DOSE; MINIMALLY INVASIVE SURGERY; MOLECULAR DYNAMICS; MULTIMODALITY CANCER THERAPY; MULTIPLE MYELOMA; NAUSEA; NEPHROTOXICITY; NONHUMAN; OSSIFICATION; OSTEOCLAST; OSTEOLYSIS; OSTEOPENIA; OVERALL SURVIVAL; PATHOGENESIS; PATHOLOGIC FRACTURE; PATHOPHYSIOLOGY; PERCUTANEOUS VERTEBROPLASTY; PRIORITY JOURNAL; QUALITY OF LIFE; RISK; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; VERTEBRA FRACTURE; VOMITING;

ANTINEOPLASTIC AGENTS; BONE DENSITY CONSERVATION AGENTS; BONE DISEASES; DIPHOSPHONATES; FRACTURES, SPONTANEOUS; HUMANS; LIFE STYLE; MULTIPLE MYELOMA; PAIN;

EID: 33746375016     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2005.11.035     Document Type: Article

References (94)

1. Mundy G.R., and Bertoline D.R. Bone destruction and hypercalcemia in plasma cell myeloma. Seminars in Oncology 13 (1986) 291-299
2. Kyle R.A. Multiple myeloma, review of 869 cases. Mayo Clin Proc 50 (1975) 29-40
3. Belch A.R., Bergsagel D.E., Wilson K., et al. Effect of daily etidronate on the osteolysis of multiple myeloma. J Clin Oncol 9 (1991) 1397-1402
4. Kyle R.A., Jowsey J., Kelly P.J., et al. Multiple myeloma bone disease. The comparative effect of sodium fluoride and calcium carbonate or placebo. N Engl J Med 293 (1975) 1334-1338
5. Lacey D.L., Timms E., Tan H.L., Kelley M.J., Dunstan C.R., et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93 2 (1998) 165-176
6. Fuller K., Wong B., Fox S., Choi Y., and Chambers T.J. TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. J Exp Med 188 5 (1998) 997-1001
7. Stashenko P., Dewhirst F.E., Peros W.J., et al. Synergistic interactions between interleukin 1, tumor necrosis factor, and lymphotoxin in bone resorption. J Immunol 138 (1987) 1464-1468
8. Mundy G.R. Mechanisms of osteolytic bone destruction. Bone 12 (1991) S1-S6 Suppl 1
9. Roodman G.D. Pathogenesis of myeloma bone disease. Blood Cells Mol Dis 32 2 (2004) 290-292
10. Pearse RN, Sordillo EM, Yaccoby S, Wong BR, Liau DF, Colman N, et al. Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11581-6. Epub 2001 Sep 18.
11. Giuliani N., Bataille R., Mancini C., Lazzaretti M., and Barille S. Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. Blood 98 13 (2001) 3527-3533
12. Standal T., Seidel C., Hjertner O., Plesner T., Sanderson R.D., Waage A., et al. Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells. Blood 100 8 (2002) 3002-3007
13. Tian E., Zhan F., Walker R., et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 349 (2003) 2483-2494
14. Oshima T., Abe M., Asano J., Hara T., Kitazoe K., Sekimoto E., et al. Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2. Blood 106 9 (2005) 3160-3165 Epub 2005 Jul 19
15. Bataille R., Chappard D., and Klein B. Mechanisms of bone lesions in multiple myeloma. Hematol Oncol Clin North Am. 6 2 (1992) 285-295
16. Barille S., Collette M., Bataille R., and Amiot M. Myeloma cells upregulate interleukin-6 secretion in osteoblastic cells through cell-to-cell contact but downregulate osteocalcin. Blood. 86 8 (1995) 3151-3159
17. Chauhan D., Uchiyama H., Akbarali Y., et al. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. Blood 87 (1996) 1104
18. Cozzolino F., Torcia M., Aldinucci D., Rubartelli A., Miliani A., Shaw A.R., et al. Production of interleukin-1 by bone marrow myeloma cells. Blood 74 1 (1989) 380-387
19. Kawano M., Tanaka H., Ishikawa H., Nobuyoshi M., Iwato K., Asaoku H., et al. Interleukin-1 accelerates autocrine growth of myeloma cells through interleukin-6 in human myeloma. Blood 73 8 (1989) 2145-2148
20. Lacy M.Q., Donovan K.A., Heimbach J.K., et al. Comparison of interleukin-1 beta expression by in situ hybridization in monoclonal gammopathy of undetermined significance and multiple myeloma. Blood 93 (1999) 300
21. Garrett I.R., Durie B.G., Nedwin G.E., et al. Production of lymphotoxin, a bone-resorbing cytokine, by cultured human myeloma cells. N Engl J Med 317 (1987) 526
22. Hjertner O., Torgersen M.L., Seidel C., et al. Hepatocyte growth factor (HGF) induces interleukin-11 secretion from osteoblasts: A possible role for HGF in myeloma-associated osteolytic bone disease. Blood 94 (1999) 3883
23. Choi S.J., Cruz J.C., Craig F., et al. Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma. Blood 96 (2000) 671
24. Borset M., Hjorth-Hansen H., Seidel C., et al. Hepatocyte growth factor and its receptor c-met in multiple myeloma. Blood 88 (1996) 3998
25. Suzuki A., Takahashi T., Okuno Y., et al. Production of parathyroid hormone-related protein by cultured human myeloma cells. Am J Hematol 45 (1994) 88
26. Kyle R.A. Multiple myeloma, review of 869 cases. Mayo Clin Proc 50 (1975) 29-40
27. Angtuaco E.J., Justus M., Sethi R., et al. Analysis of compression fractures in patients with newly diagnosed multiple myeloma on comprehensive therapy (abstr). Radiology 221 P (2001) 138
28. Moulopoulos L.A., Dimopoulos M.A., Alexanian R., et al. Multiple myeloma: MR patterns of response to treatment. Radiology 193 (1994) 441-446
29. Lecouvet F.E., Malghem J., Michaux L., et al. Vertebral compression fractures in multiple myeloma. II. Assessment of fracture risk with MR imaging of spinal bone marrow. Radiology 204 (1997) 201-205
30. Berenson J.R., Lichtenstein A., Porter L., et al. Efficacy of pamidronate in reducing the skeletal events in patients with advanced multiple myeloma. N Engl J Med 334 (1996) 488-493
31. Lecouvet F.E., Vande Berg B.C., Maldague B.E., et al. Vertebral compression fractures in multiple myeloma. I. Distribution and appearance at MR imaging. Radiology 204 (1997) 195-199
32. Melton III L.J., Rajkumar S.V., Khosla S., Achenbach S.J., Oberg A.L., and Kyle R.A. Fracture risk in monoclonal gammopathy of undetermined significance. J Bone Miner Res 19 1 (2004) 25-30
33. Melton III L.J., Kyle R.A., Achenbach S.J., Oberg A.L., and Rajkumar S.V. Fracture risk with multiple myeloma: a population-based study. J Bone Miner Res 20 3 (2005) 487-493 Epub 2004 Nov 29
34. Bataille R., Chappard D., and Basle M.F. Quantifiable excess of bone resorption in monoclonal gammopathy is an early symptom of malignancy: a prospective study of 87 bone biopsies. Blood 87 11 (1996) 4762-4769
35. Bosch A., and Frias Z. Radiotherapy in the treatment of multiple myeloma. Int J Rad Onc Biol Phys 15 (1988) 1363-1369
36. Adamietz I.A., Schober C., Schulte R.W.M., et al. Palliative radiotherapy in plasma cell myeloma. Radiotherapy and Oncology 20 (1991) 111-116
37. Rostom A.Y. A review of the place of radiotherapy in myeloma with emphasis on whole body irradiation. Hematological Oncology 6 (1988) 193-198
38. Giles F.J., McSweeney E.N., Richards J.D.M., et al. Prospective randomised study of double hemibody irradiation with and without subsequent maintenance recombinant alpha 2b interferon on survival in patients with relapsed multiple myeloma. Eur J Cancer 28A (1992) 1392-1395
39. Lecouvet F., Richard F., Vande Berg B., et al. Long-term effects of localized spinal radiation therapy on vertebral fractures and focal lesions appearance in patients with multiple myeloma. Brit J Haematol 96 (1997) 743-745
40. Catell D., Kogen Z., Donahue B., et al. Multiple myeloma of an extremity: Must the entire bone be treated. Int J Radiation Oncology Biol Phys 40 (1998) 117-119
41. 166Ho-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma: Results of two phase 1/2 trials. Blood 102 (2003) 2684-2691
42. Dispenzieri A., Wiseman G.A., Lacy M.Q., et al. A phase I study of 153Sm-EDTMP with fixed high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma. Leukemia 19 (2004) 118-125
43. Iuliano F, Molica S, Abruzzese E, Peta A, Toraldo A, Palermo S. Samarium-153 Sm-EDTMP and zoledronic acid present synergistic action and are able to control pain and significantly improve QOL in elderly patients with multiple myeloma. Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post Meeting Edition) (July 15 Suppl.), 2004: Abstract 6737.
44. Goel A., Dispenzieri A., Greipp P.R., Witzig T.E., Mesa R.A., and Russell S.J. PS-341-mediated selective targeting of multiple myeloma cells by synergistic increase in ionizing radiation-induced apoptosis. Exp Hematol. 33 7 (2005) 784-795
45. Ansiaux R., Baudelet C., Jordan B.F., Beghein N., Sonveaux P., De Wever J., et al. Thalidomide radiosensitizes tumors through early changes in the tumor microenvironment. Clin Cancer Res 11 2 Pt 1 (2005) 743-750
46. Monzen H., Griffin R.J., Williams B.W., Amano M., Ando S., and Hasegawa T. Study of arsenic trioxide-induced vascular shutdown and enhancement with radiation in solid tumor. Radiat Med. 22 4 (2004) 205-211
47. Mirels H. Metastatic disease in long bones. A proposed scoring system for diagnosing impending pathologic fractures. Clin Orthop Relat Res 249 (1989) 256-264
48. Healey J.H., and Brown H.K. Complications of bone metastases-surgical management. Cancer 88 suppl 12 (2000) 2940-2951
49. Barr J.D. Point of view: An in vivo comparison of the potential for extravertebral cement leak after vertebroplasty and kyphoplasty. Spine 27 (2002) 2178-2179
50. Jensen M.E., Evans A.J., Mathis J.M., et al. Percutaneous polymethylmethacrylate vertebroplasty in the treatment of osteoporotic vertebral body compression fractures: Technical aspects. Am J Neuroradiol 18 (1997) 1897-1904
51. Lieberman I.H., Dudeney S., Reinhardt M.-.K., and Bell G. Initial outcome and efficacy of "kyphoplasty" in the treatment of painful osteoporotic vertebral compression fractures. Spine 26 (2001) 1631-1638
52. Lieberman I., and Reinhardt M.K. Vertebroplasty and kyphoplasty for osteolytic vertebral collapse. Clin Orthop 415 Suppl (2003) S176-S186
53. Dudeny S., Lieberman I.H., Reinhardt M.-.K., and Hussein M. Kyphoplasty in the treatment of osteolytic vertebral compression fractures as a result of multiple myeloma. J Clin Oncol 20 (2002) 2382-2387
54. Green J.R., and Rogers M.J. Pharmacologic profile of zoledronic acid: a highly potent inhibitor of bone resorption. Drug Dev Res 55 (2002) 210-224
55. Lahtinen R., Laakso M., Palva I., et al. Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Lancet 340 (1992) 1049-1052
56. Heim M.E., Clemens M.R., Queisser W., et al. Prospective randomized trial of dicholoromethylene bisphosphonate (clodronate) in patients with multiple myeloma requiring treatment: a multicenter study. Onkologie 18 (1995) 439-448
57. McCloskey E.V., MacLennan C.M., Drayson M.T., et al. A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. Brit J Haematol 101 (1998) 317-325
58. Brincker H., Westin J., Abildgaard N., et al. Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double-blind placebo-controlled trial. Brit J of Haematol 101 (1998) 280-286
59. Man Z., Otero A.B., Rendo P., et al. Use of pamidronate for multiple myeloma osteolytic lesions. Lancet 335 (1990) 663
60. Purohit O.P., Anthony C., Radstone C.R., et al. High-dose intravenous pamidronate for metastatic bone pain. Brit J Cancer 70 (1994) 554-558
61. Berenson J., Lichtenstein A., Porter L., et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. J of Clin Oncol 16 (1998) 593-602
62. Berenson J.R., Lichtenstein A., Porter L., et al. Efficacy of pamidronate in reducing the skeletal events in patients with advanced multilpe myeloma. N Engl J Med 334 (1996) 488-493
63. Menssen H.D., Saklova A., Fontana A., et al. Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in pateints with advanced mutliple myeloma. J Clin Oncol 20 (2002) 2353-2359
64. Body J.J., Lichinitser M.R., Diehl I., et al. Double blind-placebo controlled trial of intravenous ibandronate in breast cancer metastatic to bone. Proc Am Soc Clin Oncol 35 (1999) 575a abstr 2222
65. Green J.R., Muller K., and Jaeggi K.A. Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res 9 (1994) 745-751
66. Berenson J.R., Vescio R., Henick K., et al. A phase I open label, dose ranging trial of intravenous bolus zolderonic acid, a novel bisphosphonate, in cancer patients with metastatic bone disease. Cancer 91 (2001) 144-154
67. Berenson J., Vescio R., Rosen L.S., et al. A phase I dose-ranging trial of monthly infusions of zoledronic acid for the treatment of metastatic bone disease. Clin Cancer Res 7 (2001) 478-485
68. Berenson J., Rosen L.S., Howell A., et al. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer 91 (2001) 1191-1200
69. Rosen L.S., Gordon D., Antonio B.S., et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: A phase III, double-blind, comparative trial. Cancer J 7 (2001) 377-387
70. Major P., Lortholary A., Hon J., et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: A pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 19 (2001) 558-567
71. Rosen L.S., Gordon D., Kaminski M., et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disocium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: A randomized, double-blind, multicenter, comparative trial. Cancer 98 (2003) 1735-1744
72. Chang J.T., Green L., Beitz J., Tarassoff P., Hei Y.-.J., and Maladorno D. Letters to the Editor: Renal failure with the use of zoledronic acid. N Engl J Med 349 (2003) 1676-1679
73. Ruggiero S.L., Mehrotra B., Rosenberg T.J., and Engroff S.L. Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases. J Oral Maxillofac Surg 62 (2004) 527-534
74. Shipman C.M., Croucher P.I., Russell R.G., Helfrich M.H., and Rogers M.J. The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway. Cancer Res. 58 23 (1998) 5294-5297
75. Takahashi R., Shimazaki C., Inaba T., Okano A., Hatsuse M., Okamoto A., et al. A newly developed bisphosphonate, YM529, is a potent apoptosis inducer of human myeloma cells. Leuk Res. 25 1 (2001) 77-83
76. Radl J., Croese J.W., Zircher C., et al. Influence of treatment with APD-bisphosphonate on the bone lesions in the mouse 5T2 multiple myeloma. Cancer 55 (1985) 1030-1040
77. Corso A., Ferretti E., Lunghi M., Zappasodi P., Mangiacavalli S., De Amici M., et al. Zoledronic acid down-regulates adhesion molecules of bone marrow stromal cells in multiple myeloma: a possible mechanism for its antitumor effect. Cancer 104 1 (2005) 118-125
78. Aparicio A., Gardner A., Tu Y., Savage A., Berenson J., et al. In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates. Leukemia 12 (1998) 220-229
79. Savage A.D., Belson D.J., Vescio R.A., et al. Pamidronate reduces IL-6 production by bone marrow stroma from multiple myeloma patients. Blood 88 (1996) 105a
80. Wood J., Bonjean K., Ruetsz S., et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 302 (2002) 1055-1061
81. Fournier P., Boissier S., Filleur S., et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 62 (2002) 6538-6544
82. Tassone P., Forciniti S., Galea E., et al. Growth inhibition and synergistic induction of apoptosis by zoledronate and dexamethasone in human myeloma cell lines. Leukemia 14 (2000) 841-844
83. Ochiai N., Yamada N., Uchida R., Fuchida S., Okano A., Okamoto M., et al. Nitrogen-containing bisphosphonate incadronate augments the inhibitory effect of farnesyl transferase inhibitor tipifarnib on the growth of fresh and cloned myeloma cells in vitro. Leuk Lymphoma 46 11 (2005) 1619-1625
84. Ochiai N., Yamada N., Uchida R., Fuchida S., Okano A., Hatsuse M., et al. Combination therapy with thalidomide, incadronate, and dexamethasone for relapsed or refractory multiple myeloma. Int J Hematol 82 3 (2005) 243-247
85. Greipp P., Facon T., Williams C.D., et al. A single subcutaneous dose of an osteoprotegerin (OPG) construct (AMGN-0007) causes a profound and sustained decrease in bone resorption comparable to standard intavenous bisphosphonate in patients with multiple myeloma. Blood 98 (2001) 775a
86. Shipman C.M., and Croucher P.I. Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells. Cancer Res 63 (2003) 912-916
87. Sordillo E.M., and Pearse R.N. RANK-Fc: A therapeutic antagonist for RANK-L in myeloma. Cancer 97 3 Suppl (2003) 802-812
88. Oyajobi B.O., Franchin G., Williams P.J., Pulkrabek D., Gupta A., Munoz S., et al. Dual effects of macrophage inflammatory protein-1alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease. Blood 102 1 (2003) 311-319 Epub 2003 Mar 20
89. de Donk N.W.C.J., Lokhorst H.M., Nijhuis E.H.J., et al. Geranylgeranylated proteins are involved in the regulation of myeloma cell growth. Clin Can Res 11 (2005) 429-439
90. Courneya K.S., Keats M.R., and Turner A.R. Physical exercise and quality of life in cancer patients following high dose chemotherapy and autologous bone marrow transplantation. Psychooncology 9 2 (2000) 127-136
91. Rosen L.S., Gordon D., Kaminski M., et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 7 (2001) 377-387
92. Saad F., Gleason D.M., Murray R., et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94 (2002) 1458-1468
93. Green J.R., Müller K., and Jaeggi K.A. Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res 9 (1994) 745-751
94. Berenson J., Hillner B., Kyle R., et al. American Society of Clinical Oncology Clinical Practice Guidelines: The role of bisphosphonates in multiple myeloma. J Clin Oncol 20 (2002) 3719-3736